Company Information

  

Address: 167 SIDNEY STREET  
City: CAMBRIDGE 
State: MA 
Zip Code: 02139 
Telephone: 617-679-5500 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. We use two distinct proprietary drug discovery technology platforms to design and develop drug candidates: our Toll-like receptor, or TLR, targeting technology and our nucleic acid chemistry technology (formerly referred to as our third generation antisense, or 3GA, technology). We developed these platforms based on our scientific expertise and pioneering work with synthetic oligonucleotides as therapeutic agents. Using our TLR targeting technology, we design synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. In addition, using our nucleic acid chemistry technology, we are developing drug candidates to turn off the messenger RNA, or mRNA, associated with disease causing genes.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2018-22.32NAN/E
03/2018-26.88NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.09Total Liab/Total Assets0.09
Net Inc/Total Assets-0.56Total Liab/Inv Cap0.10
Net Inc/Inv Cap-0.61Total Liab/Comm Equity0.02
Pretax Inc/Net Sales-73.15Interest Coverage Ratio-1318.68
Net Inc/Net Sales-73.15Curr Debt/Equity0.00
Cash Flow/Net Sales-61.26LTD/EquityNA
SG&A/NetSales18.53Total Debt/Equity0.00
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio11.54
Inventory TurnoverNACurrent Ratio11.54
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap0.01Inv/Curr AssetsNA
Net Sales/PP&E0.61  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) 0.16 0.26 0.17 0.16
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 5.58 6.98 4.83 3.92
Operating Income -16.30 -20.28 -15.02 -14.67
Interest Exp 0.00 0.01 0.01 0.01
Pretax Income -16.03 -20.10 -14.93 -14.53
Other Income 0.27 0.19 0.10 0.15
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -16.03 -20.10 -14.93 -14.53

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 94.05 107.46 112.63 65.34
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 97.97 110.11 116.62 69.01
Net Property, Plant & Equipment 1.23 1.32 1.47 1.41
Total Assets 99.51 111.75 118.42 70.75
Liabilities        
Accounts Payable 13.84 11.89 9.33 6.97
Debt in Current Liabilities 0.00 0.13 0.21 0.29
Total Current Liabilities 14.07 12.40 10.11 7.82
Long-Term Debt NA NA 0.00 0.00
Total Liabilities 14.45 12.87 10.72 8.67
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.03 0.22 0.20 0.15
Retained Earnings -640.62 -624.59 -604.49 -589.57
Treasury Stock NA NA NA NA
Total Stockholders' Equity 85.07 98.88 107.70 62.08
Total Liabilities and Stockholders' Equity 99.51 111.75 118.42 70.75

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -13.91 -14.75 -11.50 -11.88
Net Cash Provided by Investing Activities -0.03 -0.01 1.29 1.18
Net Cash Provided by Financing Activities 0.52 9.59 58.89 -0.01

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.05-18.23--
12/20140.07-38.64--
12/20150.25-48.56--
12/201616.20-38.39--
12/20170.90-65.98--
Growth Rates109.30----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1812046,185--




Report Date : 9/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.